Sanford Shattil, MD, Stepping Down as Hematology-Oncology Chief; Remains Fellowship Program Director

Announced August 21, 2014, by Wolfgang H. Dillmann, MD, Helen M. Ranney Distinguished Professor and Chair of the Department of Medicine

Sanford Shattil, MD

Sanford Shattil, MD

Please join the Department of Medicine in extending a sincere thank you to Sanford (Sandy) Shattil, MD, who will be stepping down as chief of the Division of Hematology-Oncology after ten years of service. He will be succeeded by Dr. Razelle Kurzrock.

Dr. Shattil will remain the director of the Hematology-Oncology Fellowship Training Program.

Dr. Shattil earned his Bachelor of Arts in psychology at the University of Illinois in Champaign-Urbana in 1964 and went on to receive his medical degree from the University of Illinois, College of Medicine in Chicago in 1968.

Wolfgang H. Dillmann, MD

Wolfgang H. Dillmann, MD

He completed his residency in internal medicine on the Harvard Medical Service of the Boston City Hospital and a fellowship in hematology at Boston City Hospital’s storied Thorndike Memorial Laboratory.

After a stint in the U.S. Public Health Service in San Francisco, he moved to the University of Pennsylvania in 1973, where he rose through the ranks to become professor of medicine and chief of hematology-oncology.

Razelle Kurzrock, MD

Razelle Kurzrock, MD

In 1995 he moved to The Scripps Research Institute in La Jolla, and in 2004 he was recruited to become division chief and professor of medicine at UCSD.

During Dr. Shattil’s tenure as the chief of hematology-oncology at UCSD, he has overseen major growth in the patient care, research and educational missions of the division. His vision has been to foster the careers of faculty and fellows in the context of all aspects of the division’s multiple missions and to work with other leaders at the Moores Cancer Center in expanding clinical services in a patient-centric manner.

Dr. Shattil will remain the department’s director of the Hematology-Oncology Fellowship Training Program, a role in which he has served since 2008. He will also continue his long-standing NIH-supported research program into basic and translational aspects of integrin adhesion receptor function for which he is recognized internationally, and he will maintain his clinical hematology practice, both in the inpatient setting and at Moores.

Please join me in expressing our sincere appreciation to Dr. Sandy Shattil for bringing his talents and expertise to both the Division of Hematology-Oncology and the Department of Medicine. We look forward to his continued service.